Mani Foroohar
Stock Analyst at Leerink Partners
(2.38)
# 2,441
Out of 5,182 analysts
172
Total ratings
47.92%
Success rate
-3.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAMP Camp4 Therapeutics | Maintains: Outperform | $8 → $9 | $4.47 | +101.34% | 2 | Apr 2, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $27 → $29 | $13.13 | +120.87% | 5 | Mar 3, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $102 → $104 | $74.79 | +39.06% | 17 | Mar 3, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $120 → $118 | $94.17 | +25.31% | 12 | Feb 26, 2026 | |
| RGNX REGENXBIO | Maintains: Outperform | $16 → $20 | $8.53 | +134.47% | 11 | Dec 15, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $75 → $86 | $73.15 | +17.57% | 16 | Dec 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $370 → $351 | $318.85 | +10.08% | 12 | Dec 15, 2025 | |
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $49.20 | -63.41% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $5.72 | +249.65% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.55 | +97.18% | 13 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $45 → $10 | $23.23 | -56.95% | 2 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $3.11 | +92.93% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $27 | $9.48 | +184.81% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $72 | $20.69 | +247.99% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $7.28 | +202.20% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $10.92 | +19.05% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $11.58 | +150.43% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $6.69 | +363.38% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.69 | +907.77% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $61.03 | -34.46% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.67 | +162.17% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $24.66 | +212.25% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $4.82 | +24.48% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $49.51 | +53.50% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.94 | +1,652.58% | 4 | May 12, 2022 |
Camp4 Therapeutics
Apr 2, 2026
Maintains: Outperform
Price Target: $8 → $9
Current: $4.47
Upside: +101.34%
Intellia Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $27 → $29
Current: $13.13
Upside: +120.87%
Ionis Pharmaceuticals
Mar 3, 2026
Maintains: Outperform
Price Target: $102 → $104
Current: $74.79
Upside: +39.06%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Outperform
Price Target: $120 → $118
Current: $94.17
Upside: +25.31%
REGENXBIO
Dec 15, 2025
Maintains: Outperform
Price Target: $16 → $20
Current: $8.53
Upside: +134.47%
BridgeBio Pharma
Dec 15, 2025
Maintains: Outperform
Price Target: $75 → $86
Current: $73.15
Upside: +17.57%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintains: Market Perform
Price Target: $370 → $351
Current: $318.85
Upside: +10.08%
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $49.20
Upside: -63.41%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $5.72
Upside: +249.65%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.55
Upside: +97.18%
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $23.23
Upside: -56.95%
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $3.11
Upside: +92.93%
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $9.48
Upside: +184.81%
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $20.69
Upside: +247.99%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $7.28
Upside: +202.20%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $10.92
Upside: +19.05%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $11.58
Upside: +150.43%
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $6.69
Upside: +363.38%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.69
Upside: +907.77%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $61.03
Upside: -34.46%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.67
Upside: +162.17%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $24.66
Upside: +212.25%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $4.82
Upside: +24.48%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $49.51
Upside: +53.50%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.94
Upside: +1,652.58%